Selected Publications

Mittelman M, Henry DH, Glaspy JA, Tombak A, Harrup R, Kim I, Mądry K, Grabowska B, Lee T, Modelska K.: Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: MATTERHORN phase 3, double-blind, randomized controlled trial. Am J Hematol. June 2024 Notes: DOI: 10.1002/ajh.27410.

David Henry: ASCO 2024: Abstract Recommendations From Dr. David Henry. PracticeUpdates May 2024.

Gina Nicholson 1, Katherine B Carlson 2, Rohini K Hernandez 2, Jennifer Schenfeld 2, Benoit Cadieux 3, David Henry 4, Vitor Jose De Sousa Barbosa 3, Hossam Saad 3: Treatment Patterns of Bone-targeting Agents Among Solid Tumor Patients with Bone Metastases. American Journal of Clinical Oncology January 2024.

Mittelman M, Henry DH, Glaspy JA, Tombak A, Harrup R, Kim I, Mądry K, Grabowska B, Lee T, Modelska K: Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: MATTERHORN phase 3, double-blind, randomized controlled trial. Am J Hematology 99(9): 1778-1789, 2024.

David Henry: A commentary on: Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA. PracticeUpdate 2024.

David Henry: A commentary on: Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. Practiceupdate 2024.

David Henry: CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer. Practice Update December 2023.

Lakshmi Rajdev MD, MS, Chia-Ching Jackie Wang MD, Himanshu Joshi MBBS, MPH, MSc, PhD, Shelly Lensing MS, Jeannette Lee PhD, Juan Carlos Ramos MD, Robert Baiocchi MD, PhD, Lee Ratner MD, PhD, Paul G. Rubinstein MD, Richard Ambinder MD, PhD, David Henry MD, Howard Streicher MD, Richard F. Little MD, MPH, Elizabeth Chiao MD, MPH, Dirk P. Dittmer PhD, Mark H. Einstein MD, MS, Ethel Cesarman MD, PhD, Ronald Mitsuyasu MD, Joseph A. Sparano MD: Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study. American Cancer Society Journals November 2023.

Paul G Rubinstein, MD, Page C Moore, PhD, Milan Bimali, PhD, Jeanette Y Lee, PhD, Michelle A Rudek, PhD, Amy Chadburn, MD, Lee Ratner, MD, David H Henry, MD, Ethel Cesarman, MD, Camille E DeMarco, MPH, Dominique Costagliola, PhD, Yassine Taoufik, PhD, Juan Carlos Ramos, MD, Elad Sharon, MD, Erin G Reid, MD, Richard F Ambinder, MD, Ronald Mitsuyasu, MD, Nicolas Mounier, MD, Caroline Besson, MD, Ariela Noy, MD for the AIDS Malignancy Consortium and the Lymphoma Study Association † : Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial. The Lancet 10(8): E624-E632, August 2023.

David Henry: A Commentary On: Adjuvant Osimertinib for Resected EFGR-Mutated Stage Ib-IIIA NSCLC. Practice Update June 2023.